Scientific Publications by FDA Staff

Clin Infect Dis 2005 Jun 1;40(11):1673-6

Seroprevalence of human T cell leukemia virus in HIV antibody-negative populations in rural Cameroon.

Machuca A, Wood O, Lee S, Daniel S, Rios M, Wolfe ND, Carr JK, Eitel MN, Tamoufe U, Torimiro JN, Burke D, Hewlett IK

Hewlett IK, US FDA, Mol Virol Lab, OBRR,Div Emerging & Transfus Transmitted Dis, CBER, 1401 Rockville Pike HFM-315, Rockville, MD 20852 USA US FDA, Mol Virol Lab, OBRR,Div Emerging & Transfus Transmitted Dis, CBER, Rockville, MD 20852 USA Quim Farmaceut Bayer, Div Diagnost, Madrid, Spain Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA Army Hlth Res Ctr, Yaounde, Cameroon

Seven hundred forty-seven serum samples collected from humans in 4 separate rural village areas in Cameroon were examined for antibody to human T cell leukemia viruses (HTLVs) by use of an enzyme immunoassay followed by a Western blot assay. Of the 88 serum samples that the enzyme immunoassay found to be repeatedly reactive, the HTLV status of 49 samples was confirmed by Western blot assay to be HTLV type I, and the status of 6 samples was confirmed to be HTLV type II.